The DOI matches its Crossref record; 7 of the 7 references it cites were found in a registry or an index.
Neuroprogression: pathways to progressive brain changes in bipolar disorder
Open accessAbstract
Many psychiatric disorders, including bipolar disorder follow a progressive path, and manifest a variable but observable trajectory. While Kraepelin (1921) described a progressive dementing process in schizophrenia, and conceptualized the illness as a stepwise, progressive disorder, he saw bipolar disorder as having a more episodic pattern. Nevertheless, it has become clear that bipolar disorder too shares a temporal progression in phenomenology, treatment response, neurobiology and functional impairment. The notion of clinical staging, long used in oncology and medicine and more recently in psychiatry, postulates that there is a stepwise progression through a series of identifiable steps, which have characteristic features and potential treatment implications (Berk et al., 2007b; McGorry et al., 2006). The earliest stage, stage 0, applies to individuals who have known risk factors for the disorder such as genetic vulnerability, pregnancy and obstetric complications childhood psychological, physical or sexual abuse, proximal psychological stress, and substance abuse, but no overt symptoms. The prodromal stage, stages 1a and 1b comprise mild, non-specific and identifiable disorder-specific symptoms respectively. Stage 2 is the first episode of illness, and since mania is mandatory for a DSM-IV (APA, 2000) and ICD-10 (WHO, 2005) diagnosis of bipolar I, stage 2 is synonymous with the first episode of mania or hypomania. Stage 3 is that of recurrence, and is subdivided into stage 3a, with the recurrence of subthreshold symptoms; stage 3b with threshold symptoms; and stage 3c with persistent relapses. Stage 4 is the stage of treatment resistance, manifest by a persistent unremitting course. Recurrence may be self-seeding, with illness begetting a further increased risk of recurrence. A reduction in inter-episode duration with increasing number of episodes, has been known since Kraepelin, and has been extensively replicated (Kessing et al., 1998; Kraepelin, 1921; Roy-Byrne et al., 1985; Zis et al., 1980). Further support for the progressive nature of the disorder comes from clinical, neuroimaging and neurocognitive studies. The characteristic and lengthy delay between the onset of bipolar disorder and the introduction of mood-stabilizing medication (Berk et al., 2007a), is associated with a potential reduction in the likelihood of response to treatment. Lithium (Franchini et al., 1999; Swann et al., 1999), and even psychotherapy (Scott et al., 2006) may be less useful if used later in the course of illness. Structural brain changes are not consistently found at illness onset, and appear to become more evident with chronicity (Lyoo et al., 2006; Strakowski et al., 2002). Cognitive deficits are well described in the disorder, and again there is again some evidence that this is related to number of episodes (El-Badri et al., 2001; Robinson and Ferrier, 2006), although the data is rather inconsistent. One report suggested that individuals after a first or second episode showed minimal cognitive differences compared to controls in terms of cognitive functioning (Lopez et al., 2008), whereas those with chronic illness showed significant deficits when compared to both controls and early episode bipolar patients on all scales. Recurrence is further associated with poorer social adjustment (Matza et al., 2005), more hospitalizations (Goldberg and Ernst, 2002), greater suicide risk (Hawton et al., 2005), higher rates of comorbidity, especially substance abuse (Brady and Goldberg, 1996), forensic complications, and failure to meet age-specific developmental tasks (Conus and McGorry, 2002). There are a number of models for understanding this change in the nature of the illness with course. Post (1992), in his neurosensitization model, suggests that multiple episodes lead to permanent alterations in neuronal activity, which may be transduced at the level of gene expression, and these in turn may form the neurobiological basis of a greater relapse liability, and potentially poorer response to medication. The allostatic load hypothesis (Kapczinski et al., 2008), models the cumulative ‘wear and tear’ of stressors, illness itself, and aggravating factors such as substance use, and suggests that these factors are transduced through modulation of brain circuits. This is hypothesized to result in the observed structural changes, the associated cognitive decline and the reported decreasing responsiveness to therapy. This process further increases the vulnerability to future illness episodes. In this model, mood stabilizers are hypothesized to exert an effect on neurons that opposes the impact of chronic stress. The biochemical mediators of this process are incompletely understood, but are thought to include stress sensitization via cortisone, inflammatory processes, oxidative stress, mediation via GABA, thyrotropin-releasing hormone and Neuropeptide Y, and changes to neurotrophins including BDNF (Berk et al., 2008b; Post, 2007; Wadee
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Transduction of psychosocial stress into the neurobiology of recurrent affective disorder
(1992) · American Journal of Psychiatry · doi:10.1176/ajp.149.8.999 · Cited by 1,848
Oxidative stress in psychiatric disorders: evidence base and therapeutic implications
Ng, F., Berk, M., Dean, O., & Bush, A. I. (2008) · The International Journal of Neuropsychopharmacology · doi:10.1017/s1461145707008401 · Cited by 1,069
Self-citationLithium-induced increase in human brain grey matter
Moore, G. J., Bebchuk, J. M., Wilds, I. B., Chen, G., & Menji, H. K. (2000) · The Lancet · doi:10.1016/s0140-6736(00)02793-8 · Cited by 649
Scott, J., Paykel, E., Morriss, R., Bentall, R., Kinderman, P., Johnson, T., Abbott, R., & Hayhurst, H. (2006) · British Journal of Psychiatry · doi:10.1192/bjp.188.4.313 · Cited by 566
Berk, M., Copolov, D. L., Dean, O., Lu, K., Jeavons, S., Schapkaitz, I., Anderson-Hunt, M., & Bush, A. I. (2008) · Biological Psychiatry · doi:10.1016/j.biopsych.2008.04.022 · Cited by 500
Self-citationHistory of illness prior to a diagnosis of bipolar disorder or schizoaffective disorder
Berk, M., Dodd, S., Callaly, P., Berk, L., Fitzgerald, P., de Castella, A. R., Filia, S., Filia, K., Tahtalian, S., Biffin, F., et al. (2007) · Journal of Affective Disorders · doi:10.1016/j.jad.2007.01.027 · Cited by 217
Self-citationGlutathione: a novel treatment target in psychiatry
Berk, M., Ng, F., Dean, O., Dodd, S., & Bush, A. I. (2008) · Trends in Pharmacological Sciences · doi:10.1016/j.tips.2008.05.001 · Cited by 183
Self-citation
Cited by
Grande, I., Berk, M., Birmaher, B., & Vieta, E. (2016) · The Lancet · doi:10.1016/s0140-6736(15)00241-x · Cited by 1,710
Self-citationMaes, M., Galecki, P., Chang, Y. S., & Berk, M. (2011) · Progress in Neuro-Psychopharmacology and Biological Psychiatry · doi:10.1016/j.pnpbp.2010.05.004 · Cited by 1,140
Self-citationVieta, E., Berk, M., Schulze, T. G., Carvalho, A. F., Suppes, T., Calabrese, J. R., Gao, K., Miskowiak, K. W., & Grande, I. (2018) · Nature Reviews Disease Primers · doi:10.1038/nrdp.2018.8 · Cited by 891
Self-citationPotential Mechanisms of Action of Lithium in Bipolar Disorder: Current Understanding
Malhi, G. S., Tanious, M., Das, P., Coulston, C. M., & Berk, M. (2013) · CNS Drugs · doi:10.1007/s40263-013-0039-0 · Cited by 453
Self-citationCytokines in bipolar disorder vs. healthy control subjects: A systematic review and meta-analysis
Munkholm, K., Braüner, J. V., Kessing, L. V., & Vinberg, M. (2013) · Journal of Psychiatric Research · doi:10.1016/j.jpsychires.2013.05.018 · Cited by 402
Metadata
- Authors
- Berk, M.
- Venue
- The International Journal of Neuropsychopharmacology
- Publisher
- Oxford University Press (OUP)
- Published
- 2008-10-16
- Volume
- 12
- Issue
- 04
- Pages
- 441
- ISSN
- 1461-1457 (ISSN-L)
- 1469-5111
- OpenAlex
- W2066062522
- Cited by
- 205
- References
- 7
- FWCI
- 5.64
- Type
- journal article
- Language
- en
- Open access
- bronze
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Neuroprogression: pathways to progressive brain changes in bipolar disorder. https://app.cochat.ai/papers/10.1017/s1461145708009498
- The paper
- Berk, M. (2009). Neuroprogression: pathways to progressive brain changes in bipolar disorder. The International Journal of Neuropsychopharmacology. https://doi.org/10.1017/s1461145708009498
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.